O'Connor Shirin sold $1.4M of MYRG

O'Connor Shirin sold 3,159 shares of MYR GROUP INC. (MYRG) at an average of $447.19 ($442.35–$452.94, $1.41M total) across 8 trades on 2026-06-01.

Original reporting
SEC EDGAR · O'Connor Shirin
Published Jun 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:50 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MYRG
Bearish
medium confidence
Mentioned
$MYRG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYRGBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, which can influence short‑term trading decisions.

02

Market read

New insider sale information may affect MYRG's short‑term price dynamics.

03

What to watch

Potential upcoming corporate actions or financing needs that prompted the director's cash requirement.

Relevance 6/10Novelty 4/10Timing: post‑market filing on 2026‑06‑02

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$MYRGBearishMedium confidence
Context

Director O'Connor Shirin sold 3,159 shares of MYR Group Inc. for $1.4M via open‑market transactions on 2026‑06‑01.

Expected impact

likely slight pressure as the market prices in the director's sell‑off

Evidence & confidence

A $1.4M sale by a director is material enough to attract attention but not large enough to drive a major move; investors often view director sales as a bearish cue.

Market effects

Minimal impact on the broader biotech/health‑care sector; the sale is company‑specific.

No discernible regional effect; the filing is U.S.‑based.

Limited to investors tracking MYR Group; no global market relevance.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals, so the stock may remain stable.

Key entities

  • MYR Group Inc.

    U.S. listed biotech firm (ticker MYRG).

  • O'Connor Shirin

    Director of MYR Group who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MYRGMed

KeyBanc upgrades MYR Group stock rating on balanced portfolio

KeyBanc upgraded MYR Group (NASDAQ:MYRG) to Overweight with a $361 price target, citing its balanced portfolio and strong fundamentals. The stock is down 44% in six months but is considered undervalued. MYR Group reported Q3 2026 earnings of $3.82 per share on $1.26B revenue, beating estimates, with a 38% increase in backlog to $3.68B. Revenue grew 32% YoY, driven by strong demand in commercial, industrial, and transmission sectors.

$MYRGMedAI 9/10

MYR Group (MYRG) Q3 2026 Earnings Call Transcript

MYR Group (MYRG) reported Q3 2026 record revenues of $1.26B, up 32% YoY, with T&D and C&I segments growing 10% and 58% respectively. Net income rose 86% to $60M, while backlog reached $3.68B. The company attributed growth to acquisitions and market demand, and announced a $100M share repurchase program.

$MYRGMedAI 8/10

What MYR Group (MYRG) Said on Its Q3 Earnings Call

MYR Group (MYRG) reported Q3 revenue of $555M, up 10%, with gross margin expanding to 13.6%. Operating margins improved in both segments. Backlog reached a record $3.68B. Management expects 18-22% C&I revenue growth and 10-13% T&D growth next year. The company has $650M borrowing availability and a new $100M share buyback program.

$MYRGHighAI 8/10

MYR Group gains on strong earnings and revenue beat

MYR Group Inc (MYRG) reported Q3 earnings of $3.82 per share, beating estimates by $0.83, with revenue of $1.26B, up 32% YoY. Shares rose 10% in after-hours trading. Net income increased to $60M from $32.1M YoY. The company's backlog grew 38.2% to $3.68B. MYR's board approved a $100M share repurchase program.